Clinical Trial Update: Study of Efficacy of BZ019 in Large B-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for BZ019 in Large B-cell Lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Large B-cell Lymphoma

Drugs mentioned

• BZ019 (CD19-targeted chimeric antigen receptor T cells)

Snippet

Sponsor: Shanghai Mengchao Cancer Hospital | Conditions: Large B-cell Lymphoma | Phase 2 | Status: UNKNOWN